Eye Melanoma Market Report 2026

The eye melanoma market size has grown strongly in recent years. It will grow from $9.86 billion in 2025 to $10.69 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to advancements in ocular imaging technologies, increased cancer awareness, expansion of oncology treatment facilities, growth in diagnostic capabilities, improved survival outcomes.

The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $15.17 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to development of novel immunotherapies, increasing precision oncology adoption, growth in genetic testing, rising investment in rare cancer research, improved early screening programs. Major trends in the forecast period include growing focus on early cancer detection, rising adoption of targeted and immunotherapies, increased use of advanced ocular imaging, expansion of specialized oncology centers, growing clinical research in rare eye cancers.

The rising prevalence of eye cancer is expected to drive growth in the eye melanoma market. Eye cancer involves the abnormal and uncontrolled growth of cells within the structures of the eye. Increased awareness, improved early detection, and advancements in treatment options are fueling demand for specialized therapies and interventions. For instance, in 2025, according to the American Cancer Society, a US-based non-profit organization, there were approximately 3,140 new cases of eye and orbital cancers (primarily melanomas), including 1,620 in males and 1,520 in females. Additionally, there were about 490 deaths from these cancers, comprising 270 males and 220 females. Therefore, the rising prevalence of eye cancer is expected to propel the growth of the eye melanoma market.

Major companies in the eye melanoma market are focusing on developing targeted therapies, such as protein-kinase C (PKC) inhibitors, to address the growing need for eye-preserving and effective systemic treatments. PKC inhibitors are small-molecule agents that selectively block PKC enzymes involved in tumor growth, offering a non-surgical alternative to conventional therapies like plaque brachytherapy or enucleation. For instance, in March 2025, IDEAYA Biosciences, a US-based precision oncology company, launched darovasertib, a first-in-class PKC inhibitor for uveal melanoma. The therapy targets PKC isoforms implicated in tumor proliferation, achieving tumor shrinkage rates of approximately 82% and eye-preservation rates of 61% in Phase 2 trials. Darovasertib can be used in patients eligible for enucleation or plaque brachytherapy, providing a systemic, eye-sparing treatment option for primary uveal melanoma.

In January 2023, Health Network One, a US-based specialty benefit management company, acquired Premier Eye Care for an undisclosed amount. This acquisition aims to expand Health Network One’s provider network, enhance clinical quality, and drive innovation in ophthalmology services. Premier Eye Care, a US-based eye care services company, specializes in diagnosing and treating eye melanoma through various modalities, including surgery, radiation, and laser therapy.

Major companies operating in the eye melanoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann‑La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Bristol‑Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Amgen Inc., Castle Biosciences Inc., IDEAYA Biosciences Inc., Delcath Systems Inc., Immunocore Holdings plc, Aura Biosciences Inc., TriSalus Life Sciences Inc., Replimune Group Inc., Linnaeus Therapeutics, iOnctura, LES LABORATOIRES SERVIER, Immatics NV.

North America was the largest region in the eye melanoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eye melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the eye melanoma market by raising prices for imported imaging systems, radiotherapy equipment, targeted therapies, and immunotherapy drugs. Hospitals and oncology clinics in Asia-Pacific and Europe are most impacted due to reliance on global medical technology and pharmaceutical suppliers. These higher costs can delay diagnosis and advanced treatment access. However, tariffs are encouraging regional production of oncology drugs and diagnostic equipment, improving long-term treatment capacity.

The eye melanoma market research report is one of a series of new reports that provides eye melanoma market statistics, including eye melanoma industry global market size, regional shares, competitors with a eye melanoma market share, detailed eye melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the eye melanoma industry. This eye melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Eye melanoma is a form of cancer that develops in melanocytes, the cells responsible for producing melanin within the eye. It can occur in various parts of the eye, including the uvea, iris, and choroid. Eye melanoma is the most common primary intraocular cancer in adults and can lead to vision problems, changes in eye color, and other symptoms depending on its location and size.

The main types of eye melanoma are found in the uvea, sclera, and retina. The uvea is the middle layer of the eye, comprising the iris, ciliary body, and choroid, which contain blood vessels that supply nutrients to the eye. Various forms of radiation therapy, including plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery, are used to target and reduce uveal melanomas. Diagnosis is carried out using imaging, biopsy, and eye examinations, while treatments include surgery, radiation therapy, targeted therapy, immunotherapy, and others. These services are provided by end users such as hospitals, clinics, and academic institutions.

The eye melanoma market consists of revenues earned by entities by providing fine needle aspiration (FNA) techniques, blood testing, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The eye melanoma market also includes sales of drugs and therapeutics such as chemotherapy, cryotherapy, and photodynamic therapy (PDT). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.